13,579
次編輯
變更
江龙光
,创建页面，内容为“{| class="wikitable" style="float:right; margin: -10px 0px 10px 20px; text-align:left" |<center>''' 江龙光 '''<br><img src=" https://chem.fzu.edu.cn/__local/2/FC…”
{| class="wikitable" style="float:right; margin: -10px 0px 10px 20px; text-align:left"
|<center>''' 江龙光 '''<br><img src=" https://chem.fzu.edu.cn/__local/2/FC/80/0A3DA3157BB9FA38611E28061F8_AC709378_16198.jpg " width="180"></center><small>[https://chem.fzu.edu.cn/info/1195/8444.htm 福州大学化学学院]
</small>
|}
'''江龙光'''，男，福州大学化学学院副教授。
==人物简历==
教育经历
2005.09 - 2010.07：中国科学院福建物质结构研究所，博士/Fujian Institute of Material Structure, Chinese Academy of Sciences，Ph.D.
（导师/Supervisor：黄明东 研究员/Prof. Mingdong Huang）
2001.09 - 2005.07：贵州大学，学士/Guizhou University, Bachelor
2016.02 – ：福州大学化学学院/College of Chemistry, Fuzhou University
2018.10 - 2019.10：哈佛医学院，访问学者/Harvard Medical School，Visiting Scholar
（合作导师/Supervisor： Prof. Robert C. Flaumenhaft, MD, Ph.D. ）
2014.07 - 2014.10：奥胡斯大学，访问学者/Aarhus University, Visiting Scholar
（合作导师/Supervisor： Prof. Peter A. Andreasen, Ph.D. ）
2010.07 - 2016.01：中国科学院福建物质结构研究所，助理研究员/Fujian Institute of Material Structure, Chinese Academy of Sciences，Research Associate
《生物化学》/《Biochemistry》
《制药工程专业英语》/《Professional English for Pharmaceutical Engineering》
《综合化学实验》/《Comprehensive Chemical Experiments》
《制药工程创新创业实践》/《Pharmaceutical Engineering Innovation and Entrepreneurship Practice》
==社会兼职==
福建省生物工程学会，理事
==科研项目==
1.福建省科技创新重点项目（2021G02004），2022-2023，项目负责人
2.国家自然科学基金面上项目（82070142），2021-2024，项目负责人
3.企业横向项目，2020-2023，项目负责人
4.国家重点研发计划项目（2017YFE0103200），2018-2021，研究骨干
5.福建省自然科学基金面上项目（2018J01729），2018-2021，项目负责人
6.国家自然科学基金青年项目（31400637），2015-2017，项目负责人
7.福建省自然科学基金青年创新项目（2012J05071），2012-2015，项目负责人
==学术成果==
=== 论文 ===
(*: Equal contributions; #: co-corresponding authors)
30. Zhou Y, Wu J, Xue G, Li J, Jiang L#, Huang M#. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat. Biophys J. 2022 Aug 29:S0006-3495(22)00694-4.
29.Wang R, Yang M, Jiang L#, Huang M#. Role of Angiopoietin-Tie axis in vascular and lymphatic systems and therapeutic interventions. Pharmacol Res. 2022 Aug;182:106331.
28. Sun G, Sui Y, Zhou Y, Ya J, Yuan C, Jiang L#, Huang M#. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat. J Virol. 2021;95(19):e0086121.
27. 王蕊，黄美娟，许燕艳，袁彩，黄明东#，江龙光#，Ang-Tie轴在血管和淋巴系统相关疾病中作用的研究进展，生物工程学报，2021，37(8): 2633-2644.
26. Ma H*, Li R*, Jiang L*, Qiao S, Chen XX, Wang A, Zhang G. Structural comparison of CD163 SRCR5 from different species sheds some light on its involvement in porcine reproductive and respiratory syndrome virus-2 infection in vitro. Vet Res. 2021;52(1):97.
25 Sun G, Yang M, Jiang L#, Huang M#. Regulation of pro-σK activation: a key checkpoint in Bacillus subtilis sporulation. Environ Microbiol. 2021;23(5):2366-2373.
24 Jiang L, Yuan C, Huang M. A general strategy to inhibit serine protease by targeting its autolysis loop. FASEB J. 2021;35(2):e21259.
23. Yuan C, Guo Z, Yu S, Jiang L#, Huang M#. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discov Today. 2021;26(4):1076-1085.
22. Huang M, Li L, Shen J, Wang Y, Wang R, Yuan C, Huang M#, Jiang L#. Plasma levels of the active form of suPAR are associated with COVID-19 severity. Crit Care. 2020;24(1):704.
21. Zhou Y, Chen D, Xue G, Yu S, Yuan C, Huang M#, Jiang L#, Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA, RSC Adv., 2020,10, 34517-34526.
20. G Xue, X Xie, Y Zhou, C Yuan, M Huang#, Jiang L#. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases. Biosci Biotechnol Biochem. 2020;84(6):1153-1159.
19. Xie X, Guo N, Xue, Xie D, Yuan C, Harrison J, Li J, L. Jiang L#, Huang M#. Solution structure of SpolVB reveals mechanism of PDZ domain-regulated protease activity. Frontiers in Microbiology, 2019;10,1232.
18. Jiang J, Xie X, Li J, Persson E, Huang M. Crystal structure, epitope and functional impact of an antibody against a super-active FVIIa provide insights into allosteric mechanism. Research and Practice in Thrombosis & Haemostasis, 2019; 3(3);412-419.
17. Jiang L, Zhang X, Zhou Y, Chen Y, Luo Z, Li J, Yuan C, Huang M. Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases. RSC Advances, 2018;8, 28189.
16. Jiang L, Oldenburg E, Kromann-Hansen T, Xu P, Jensen JK, Andreasen PA, Huang M. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition. Biochim Biophys Acta. 2018;1862(9):2017-2023.
15. Sun YG*, Li R*, Jiang L*, Qiao S, Zhi Y, Chen XX, Xie S, Wu J, Li X, Deng R, Zhang G. Characterization of the interaction between recombinant porcine aminopeptidase N and spike glycoprotein of porcine epidemic diarrhea virus. Int J Biol Macromol. 2018; 117:704-712.
14. Xie X, Xue G, Jiang L#, Huang M#. Ligand Induced Conformational Transitions of Tissue Factor Ω loop, Chinese J. Struct. Chem. 2018;37(6), 961-968.
13. Xu M, Chen Y, Xu P, Andreasen PA, Jiang L#, Li J#, Huang M#. Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217. FEBS Lett. 2018;592(15):2658-2667.
12. Xu M, Xu P, Zhou X, Andreasen PA, Jiang L#, Huang M#. Crystal structures of the serine protease domain of murine plasma kallikrein, Chinese J. Struct. Chem. 2017, 36(2), 961-968.
11. Xue G, Gong L, Yuan C, Xu M, Wang X, Jiang L#, Huang M. A structural mechanism of flavonoids in inhibiting serine proteases. Food Funct. 2017;8(7):2437-2443.
10. Ma H, Qiao S, Huang M, Jiang L#, Li R#, Zhang G#. Crystal Structure of a CD163 Scavenger Receptor Cysteine-rich Domain Produced in Pichia Pastoris, Chinese J. Struct. Chem. 2017, 36(9), 961-968.
9. Ma H*, Jiang L*, Qiao S, Zhi Y, Chen XX, Yang Y, Huang X, Huang M, Li R, Zhang GP. Crystal Structure of the Fifth Scavenger Receptor Cysteine-Rich Domain (SRCR5) from Porcine CD163 Reveals an Important Residue Involved in Porcine Reproductive and Respiratory Syndrome Virus Infection. J Virol. 2017;91(3): e01897-16.
8. Jiang L, Lin L, Li R, Yuan C, Xu M, Huang JH, Huang M. Dimer conformation of soluble PECAM-1, an endothelial marker. Int J Biochem Cell Biol. 2016;77 (Pt A):102-108.
7. Jiang L, Andersen LM, Andreasen PA, Chen L, Huang M. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate. Biochim Biophys Acta-General subjects. 2016; 1860 (3):599-606.
6. Jiang L, Zhao B, Xu P, Sørensen HP, Jensen JK, Christensen A, Hosseini M, Nielsen NC, Jensen KJ, Andreasen PA, Huang M. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues. Int J Biochem Cell Biol. 2015; 62:88-92.
5. Jiang L, Botkjaer KA, Andersen LM, Yuan C, Andreasen PA, Huang M. Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem J. 2013 Jan 1; 449 (1): 161-6.
4. Jiang L*, Svane AS*, Sørensen HP, Jensen JK, Hosseini M, Chen Z, Weydert C, Nielsen JT, Christensen A, Yuan C, Jensen KJ, Nielsen NC, Malmendal A, Huang M, Andreasen PA. The Binding Mechanism of a Peptidic Cyclic Serine Protease Inhibitor. J Mol Biol. 2011;412(2), 235-50.
3. Jiang L, Yuan, C, Chen, H, Wang, Y, Zhao, B, Zhang, X, and Huang, M, Preparation and structure of a new coagulation factor XI catalytic domain for drug discovery. Chinese J. Struct. Chem. 2011;30 (7), 1021-59.
2. Jiang L, Zhao G, Bian C, Yuan C, Huang Z, Huang M. Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol. Chinese J. Struct. Chem. 2009; 28(2), pp. 253-259.
1. Jiang, L, Yu H, Yuan C, Wang J, Chen L, Edward J. Meehan, Huang Z, Huang M. The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator. Chinese J. Struct. Chem. 2009;28(11):1427-1432.
==获奖情况==
2020年度“鸿耀奖教奖”；2021年“厦航奖教奖”<ref>[https://chem.fzu.edu.cn/index.htm 福州大学化学学院]</ref>
==参考资料==
{{reflist}}
[[Category:教授]]
|<center>''' 江龙光 '''<br><img src=" https://chem.fzu.edu.cn/__local/2/FC/80/0A3DA3157BB9FA38611E28061F8_AC709378_16198.jpg " width="180"></center><small>[https://chem.fzu.edu.cn/info/1195/8444.htm 福州大学化学学院]
</small>
|}
'''江龙光'''，男，福州大学化学学院副教授。
==人物简历==
教育经历
2005.09 - 2010.07：中国科学院福建物质结构研究所，博士/Fujian Institute of Material Structure, Chinese Academy of Sciences，Ph.D.
（导师/Supervisor：黄明东 研究员/Prof. Mingdong Huang）
2001.09 - 2005.07：贵州大学，学士/Guizhou University, Bachelor
2016.02 – ：福州大学化学学院/College of Chemistry, Fuzhou University
2018.10 - 2019.10：哈佛医学院，访问学者/Harvard Medical School，Visiting Scholar
（合作导师/Supervisor： Prof. Robert C. Flaumenhaft, MD, Ph.D. ）
2014.07 - 2014.10：奥胡斯大学，访问学者/Aarhus University, Visiting Scholar
（合作导师/Supervisor： Prof. Peter A. Andreasen, Ph.D. ）
2010.07 - 2016.01：中国科学院福建物质结构研究所，助理研究员/Fujian Institute of Material Structure, Chinese Academy of Sciences，Research Associate
《生物化学》/《Biochemistry》
《制药工程专业英语》/《Professional English for Pharmaceutical Engineering》
《综合化学实验》/《Comprehensive Chemical Experiments》
《制药工程创新创业实践》/《Pharmaceutical Engineering Innovation and Entrepreneurship Practice》
==社会兼职==
福建省生物工程学会，理事
==科研项目==
1.福建省科技创新重点项目（2021G02004），2022-2023，项目负责人
2.国家自然科学基金面上项目（82070142），2021-2024，项目负责人
3.企业横向项目，2020-2023，项目负责人
4.国家重点研发计划项目（2017YFE0103200），2018-2021，研究骨干
5.福建省自然科学基金面上项目（2018J01729），2018-2021，项目负责人
6.国家自然科学基金青年项目（31400637），2015-2017，项目负责人
7.福建省自然科学基金青年创新项目（2012J05071），2012-2015，项目负责人
==学术成果==
=== 论文 ===
(*: Equal contributions; #: co-corresponding authors)
30. Zhou Y, Wu J, Xue G, Li J, Jiang L#, Huang M#. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat. Biophys J. 2022 Aug 29:S0006-3495(22)00694-4.
29.Wang R, Yang M, Jiang L#, Huang M#. Role of Angiopoietin-Tie axis in vascular and lymphatic systems and therapeutic interventions. Pharmacol Res. 2022 Aug;182:106331.
28. Sun G, Sui Y, Zhou Y, Ya J, Yuan C, Jiang L#, Huang M#. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat. J Virol. 2021;95(19):e0086121.
27. 王蕊，黄美娟，许燕艳，袁彩，黄明东#，江龙光#，Ang-Tie轴在血管和淋巴系统相关疾病中作用的研究进展，生物工程学报，2021，37(8): 2633-2644.
26. Ma H*, Li R*, Jiang L*, Qiao S, Chen XX, Wang A, Zhang G. Structural comparison of CD163 SRCR5 from different species sheds some light on its involvement in porcine reproductive and respiratory syndrome virus-2 infection in vitro. Vet Res. 2021;52(1):97.
25 Sun G, Yang M, Jiang L#, Huang M#. Regulation of pro-σK activation: a key checkpoint in Bacillus subtilis sporulation. Environ Microbiol. 2021;23(5):2366-2373.
24 Jiang L, Yuan C, Huang M. A general strategy to inhibit serine protease by targeting its autolysis loop. FASEB J. 2021;35(2):e21259.
23. Yuan C, Guo Z, Yu S, Jiang L#, Huang M#. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discov Today. 2021;26(4):1076-1085.
22. Huang M, Li L, Shen J, Wang Y, Wang R, Yuan C, Huang M#, Jiang L#. Plasma levels of the active form of suPAR are associated with COVID-19 severity. Crit Care. 2020;24(1):704.
21. Zhou Y, Chen D, Xue G, Yu S, Yuan C, Huang M#, Jiang L#, Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA, RSC Adv., 2020,10, 34517-34526.
20. G Xue, X Xie, Y Zhou, C Yuan, M Huang#, Jiang L#. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases. Biosci Biotechnol Biochem. 2020;84(6):1153-1159.
19. Xie X, Guo N, Xue, Xie D, Yuan C, Harrison J, Li J, L. Jiang L#, Huang M#. Solution structure of SpolVB reveals mechanism of PDZ domain-regulated protease activity. Frontiers in Microbiology, 2019;10,1232.
18. Jiang J, Xie X, Li J, Persson E, Huang M. Crystal structure, epitope and functional impact of an antibody against a super-active FVIIa provide insights into allosteric mechanism. Research and Practice in Thrombosis & Haemostasis, 2019; 3(3);412-419.
17. Jiang L, Zhang X, Zhou Y, Chen Y, Luo Z, Li J, Yuan C, Huang M. Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases. RSC Advances, 2018;8, 28189.
16. Jiang L, Oldenburg E, Kromann-Hansen T, Xu P, Jensen JK, Andreasen PA, Huang M. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition. Biochim Biophys Acta. 2018;1862(9):2017-2023.
15. Sun YG*, Li R*, Jiang L*, Qiao S, Zhi Y, Chen XX, Xie S, Wu J, Li X, Deng R, Zhang G. Characterization of the interaction between recombinant porcine aminopeptidase N and spike glycoprotein of porcine epidemic diarrhea virus. Int J Biol Macromol. 2018; 117:704-712.
14. Xie X, Xue G, Jiang L#, Huang M#. Ligand Induced Conformational Transitions of Tissue Factor Ω loop, Chinese J. Struct. Chem. 2018;37(6), 961-968.
13. Xu M, Chen Y, Xu P, Andreasen PA, Jiang L#, Li J#, Huang M#. Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217. FEBS Lett. 2018;592(15):2658-2667.
12. Xu M, Xu P, Zhou X, Andreasen PA, Jiang L#, Huang M#. Crystal structures of the serine protease domain of murine plasma kallikrein, Chinese J. Struct. Chem. 2017, 36(2), 961-968.
11. Xue G, Gong L, Yuan C, Xu M, Wang X, Jiang L#, Huang M. A structural mechanism of flavonoids in inhibiting serine proteases. Food Funct. 2017;8(7):2437-2443.
10. Ma H, Qiao S, Huang M, Jiang L#, Li R#, Zhang G#. Crystal Structure of a CD163 Scavenger Receptor Cysteine-rich Domain Produced in Pichia Pastoris, Chinese J. Struct. Chem. 2017, 36(9), 961-968.
9. Ma H*, Jiang L*, Qiao S, Zhi Y, Chen XX, Yang Y, Huang X, Huang M, Li R, Zhang GP. Crystal Structure of the Fifth Scavenger Receptor Cysteine-Rich Domain (SRCR5) from Porcine CD163 Reveals an Important Residue Involved in Porcine Reproductive and Respiratory Syndrome Virus Infection. J Virol. 2017;91(3): e01897-16.
8. Jiang L, Lin L, Li R, Yuan C, Xu M, Huang JH, Huang M. Dimer conformation of soluble PECAM-1, an endothelial marker. Int J Biochem Cell Biol. 2016;77 (Pt A):102-108.
7. Jiang L, Andersen LM, Andreasen PA, Chen L, Huang M. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate. Biochim Biophys Acta-General subjects. 2016; 1860 (3):599-606.
6. Jiang L, Zhao B, Xu P, Sørensen HP, Jensen JK, Christensen A, Hosseini M, Nielsen NC, Jensen KJ, Andreasen PA, Huang M. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues. Int J Biochem Cell Biol. 2015; 62:88-92.
5. Jiang L, Botkjaer KA, Andersen LM, Yuan C, Andreasen PA, Huang M. Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem J. 2013 Jan 1; 449 (1): 161-6.
4. Jiang L*, Svane AS*, Sørensen HP, Jensen JK, Hosseini M, Chen Z, Weydert C, Nielsen JT, Christensen A, Yuan C, Jensen KJ, Nielsen NC, Malmendal A, Huang M, Andreasen PA. The Binding Mechanism of a Peptidic Cyclic Serine Protease Inhibitor. J Mol Biol. 2011;412(2), 235-50.
3. Jiang L, Yuan, C, Chen, H, Wang, Y, Zhao, B, Zhang, X, and Huang, M, Preparation and structure of a new coagulation factor XI catalytic domain for drug discovery. Chinese J. Struct. Chem. 2011;30 (7), 1021-59.
2. Jiang L, Zhao G, Bian C, Yuan C, Huang Z, Huang M. Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol. Chinese J. Struct. Chem. 2009; 28(2), pp. 253-259.
1. Jiang, L, Yu H, Yuan C, Wang J, Chen L, Edward J. Meehan, Huang Z, Huang M. The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator. Chinese J. Struct. Chem. 2009;28(11):1427-1432.
==获奖情况==
2020年度“鸿耀奖教奖”；2021年“厦航奖教奖”<ref>[https://chem.fzu.edu.cn/index.htm 福州大学化学学院]</ref>
==参考资料==
{{reflist}}
[[Category:教授]]